Research programme: toll-like receptor 8 agonists and antagonists - VentiRx

Drug Profile

Research programme: toll-like receptor 8 agonists and antagonists - VentiRx

Alternative Names: VTX-294; VTX-378; VTX-763

Latest Information Update: 15 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Array BioPharma
  • Developer VentiRx Pharmaceuticals
  • Class Benzazepines; Small molecules
  • Mechanism of Action Toll-like receptor 8 agonists; Toll-like receptor 8 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders
  • No development reported Cancer; Hypersensitivity

Most Recent Events

  • 14 Feb 2017 VentiRx Pharmaceuticals has been acquired by Celgene Corporation
  • 05 Apr 2016 Preclinical development is ongoing in Autoimmune disorders in USA
  • 04 Mar 2013 Immunogenicity data from in vitro studies released by VentiRx Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top